LifeMine Therapeutics announced a $263M raise today to help accelerate the development of its novel calcineurin activation inhibitor that aims to radically change the profile of organ transplants
Co-Founder, President & CEO Greg Verdine describes the toxicity issues associated with the immuosupressive drugs that transplant recipients currently receive, and explains how LIFE-001 is different. Plus, given how the therapy is designed to safely prevent T-cell activation and proliferation, there could also ultimately be an autoimmune use case as well.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.